Composite hemangioendothelioma and its classification as a low-grade malignancy.
Identifieur interne : 001B99 ( PubMed/Checkpoint ); précédent : 001B98; suivant : 001C00Composite hemangioendothelioma and its classification as a low-grade malignancy.
Auteurs : Patricia Moody Mcnab [États-Unis] ; Brian Christopher Quigley ; L Frank Glass ; Drazen M. JukicSource :
- The American Journal of dermatopathology [ 1533-0311 ] ; 2013.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antinéoplasiques d'origine végétale (administration et posologie), Biopsie, Calendrier d'administration des médicaments, Enfant, Femelle, Grading des tumeurs, Humains, Hémangioendothéliome (), Hémangioendothéliome (anatomopathologie), Hémangioendothéliome (traitement médicamenteux), Immunohistochimie, Jeune adulte, Marqueurs biologiques tumoraux (analyse), Mâle, Paclitaxel (administration et posologie), Résultat thérapeutique, Sujet âgé, Terminologie comme sujet, Tumeurs complexes et mixtes (), Tumeurs complexes et mixtes (anatomopathologie), Tumeurs complexes et mixtes (traitement médicamenteux), Tumeurs cutanées (), Tumeurs cutanées (anatomopathologie), Tumeurs cutanées (traitement médicamenteux), Valeur prédictive des tests.
- MESH :
- administration et posologie : Antinéoplasiques d'origine végétale, Paclitaxel.
- analyse : Marqueurs biologiques tumoraux.
- anatomopathologie : Hémangioendothéliome, Tumeurs complexes et mixtes, Tumeurs cutanées.
- traitement médicamenteux : Hémangioendothéliome, Tumeurs complexes et mixtes, Tumeurs cutanées.
- Adolescent, Adulte, Adulte d'âge moyen, Biopsie, Calendrier d'administration des médicaments, Enfant, Femelle, Grading des tumeurs, Humains, Hémangioendothéliome, Immunohistochimie, Jeune adulte, Mâle, Résultat thérapeutique, Sujet âgé, Terminologie comme sujet, Tumeurs complexes et mixtes, Tumeurs cutanées, Valeur prédictive des tests.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antineoplastic Agents, Phytogenic (administration & dosage), Biomarkers, Tumor (analysis), Biopsy, Child, Drug Administration Schedule, Female, Hemangioendothelioma (chemistry), Hemangioendothelioma (classification), Hemangioendothelioma (drug therapy), Hemangioendothelioma (pathology), Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Grading, Neoplasms, Complex and Mixed (chemistry), Neoplasms, Complex and Mixed (classification), Neoplasms, Complex and Mixed (drug therapy), Neoplasms, Complex and Mixed (pathology), Paclitaxel (administration & dosage), Predictive Value of Tests, Skin Neoplasms (chemistry), Skin Neoplasms (classification), Skin Neoplasms (drug therapy), Skin Neoplasms (pathology), Terminology as Topic, Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Phytogenic, Paclitaxel.
- chemical , analysis : Biomarkers, Tumor.
- chemistry : Hemangioendothelioma, Neoplasms, Complex and Mixed, Skin Neoplasms.
- classification : Hemangioendothelioma, Neoplasms, Complex and Mixed, Skin Neoplasms.
- drug therapy : Hemangioendothelioma, Neoplasms, Complex and Mixed, Skin Neoplasms.
- pathology : Hemangioendothelioma, Neoplasms, Complex and Mixed, Skin Neoplasms.
- Adolescent, Adult, Aged, Biopsy, Child, Drug Administration Schedule, Female, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Grading, Predictive Value of Tests, Terminology as Topic, Treatment Outcome, Young Adult.
Abstract
Hemangioendotheliomas are vascular neoplasms occupying a spectrum of biological potential ranging from benign to low-grade malignancy. Composite hemangioendothelioma (CH) is one of the less commonly encountered variants exhibiting a mixture of elements of other hemangioendothelioma subtypes, such as epithelioid, retiform, and spindle cell. Some authors have identified areas histopathologically equivalent to angiosarcoma within CH, raising the question of the true nature of this neoplasm. Although CH recurs locally, there are only 3 reported cases which metastasized. To date, 26 cases (including the present case) have been described in the literature. Herein, we describe a unique case of CH arising in the background of previous radiation therapy and long-standing lymphedema (classically associated with the development of angiosarcoma-Stewart-Treves syndrome) that harbored higher grade areas but behaved as a low-grade malignant neoplasm. This, in conjunction with the many reported cases of CH-harboring angiosarcoma-like areas, and the occasional association with a history of lymphedema, raises the question of whether this variant of hemangioendothelioma may actually be an angiosarcoma that behaves prognostically better than the conventional type. After careful study of the natural disease progression of the current case and review of the literature, we discuss justification for the continued classification of CH as a low-grade malignancy.
DOI: 10.1097/DAD.0b013e31827a0d37
PubMed: 23694827
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23694827Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Composite hemangioendothelioma and its classification as a low-grade malignancy.</title><author><name sortKey="Mcnab, Patricia Moody" sort="Mcnab, Patricia Moody" uniqKey="Mcnab P" first="Patricia Moody" last="Mcnab">Patricia Moody Mcnab</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, University of South Florida College of Medicine, Tampa, FL 33612, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Cell Biology, University of South Florida College of Medicine, Tampa, FL 33612</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Quigley, Brian Christopher" sort="Quigley, Brian Christopher" uniqKey="Quigley B" first="Brian Christopher" last="Quigley">Brian Christopher Quigley</name></author><author><name sortKey="Glass, L Frank" sort="Glass, L Frank" uniqKey="Glass L" first="L Frank" last="Glass">L Frank Glass</name></author><author><name sortKey="Jukic, Drazen M" sort="Jukic, Drazen M" uniqKey="Jukic D" first="Drazen M" last="Jukic">Drazen M. Jukic</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23694827</idno><idno type="pmid">23694827</idno><idno type="doi">10.1097/DAD.0b013e31827a0d37</idno><idno type="wicri:Area/PubMed/Corpus">001B37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B37</idno><idno type="wicri:Area/PubMed/Curation">001B37</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B37</idno><idno type="wicri:Area/PubMed/Checkpoint">001B37</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Composite hemangioendothelioma and its classification as a low-grade malignancy.</title><author><name sortKey="Mcnab, Patricia Moody" sort="Mcnab, Patricia Moody" uniqKey="Mcnab P" first="Patricia Moody" last="Mcnab">Patricia Moody Mcnab</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, University of South Florida College of Medicine, Tampa, FL 33612, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Cell Biology, University of South Florida College of Medicine, Tampa, FL 33612</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Quigley, Brian Christopher" sort="Quigley, Brian Christopher" uniqKey="Quigley B" first="Brian Christopher" last="Quigley">Brian Christopher Quigley</name></author><author><name sortKey="Glass, L Frank" sort="Glass, L Frank" uniqKey="Glass L" first="L Frank" last="Glass">L Frank Glass</name></author><author><name sortKey="Jukic, Drazen M" sort="Jukic, Drazen M" uniqKey="Jukic D" first="Drazen M" last="Jukic">Drazen M. Jukic</name></author></analytic><series><title level="j">The American Journal of dermatopathology</title><idno type="eISSN">1533-0311</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antineoplastic Agents, Phytogenic (administration & dosage)</term><term>Biomarkers, Tumor (analysis)</term><term>Biopsy</term><term>Child</term><term>Drug Administration Schedule</term><term>Female</term><term>Hemangioendothelioma (chemistry)</term><term>Hemangioendothelioma (classification)</term><term>Hemangioendothelioma (drug therapy)</term><term>Hemangioendothelioma (pathology)</term><term>Humans</term><term>Immunohistochemistry</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Neoplasms, Complex and Mixed (chemistry)</term><term>Neoplasms, Complex and Mixed (classification)</term><term>Neoplasms, Complex and Mixed (drug therapy)</term><term>Neoplasms, Complex and Mixed (pathology)</term><term>Paclitaxel (administration & dosage)</term><term>Predictive Value of Tests</term><term>Skin Neoplasms (chemistry)</term><term>Skin Neoplasms (classification)</term><term>Skin Neoplasms (drug therapy)</term><term>Skin Neoplasms (pathology)</term><term>Terminology as Topic</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques d'origine végétale (administration et posologie)</term><term>Biopsie</term><term>Calendrier d'administration des médicaments</term><term>Enfant</term><term>Femelle</term><term>Grading des tumeurs</term><term>Humains</term><term>Hémangioendothéliome ()</term><term>Hémangioendothéliome (anatomopathologie)</term><term>Hémangioendothéliome (traitement médicamenteux)</term><term>Immunohistochimie</term><term>Jeune adulte</term><term>Marqueurs biologiques tumoraux (analyse)</term><term>Mâle</term><term>Paclitaxel (administration et posologie)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Terminologie comme sujet</term><term>Tumeurs complexes et mixtes ()</term><term>Tumeurs complexes et mixtes (anatomopathologie)</term><term>Tumeurs complexes et mixtes (traitement médicamenteux)</term><term>Tumeurs cutanées ()</term><term>Tumeurs cutanées (anatomopathologie)</term><term>Tumeurs cutanées (traitement médicamenteux)</term><term>Valeur prédictive des tests</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers, Tumor</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Hémangioendothéliome</term><term>Tumeurs complexes et mixtes</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Hemangioendothelioma</term><term>Neoplasms, Complex and Mixed</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Hemangioendothelioma</term><term>Neoplasms, Complex and Mixed</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hemangioendothelioma</term><term>Neoplasms, Complex and Mixed</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Hemangioendothelioma</term><term>Neoplasms, Complex and Mixed</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hémangioendothéliome</term><term>Tumeurs complexes et mixtes</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Biopsy</term><term>Child</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Predictive Value of Tests</term><term>Terminology as Topic</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Biopsie</term><term>Calendrier d'administration des médicaments</term><term>Enfant</term><term>Femelle</term><term>Grading des tumeurs</term><term>Humains</term><term>Hémangioendothéliome</term><term>Immunohistochimie</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Terminologie comme sujet</term><term>Tumeurs complexes et mixtes</term><term>Tumeurs cutanées</term><term>Valeur prédictive des tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hemangioendotheliomas are vascular neoplasms occupying a spectrum of biological potential ranging from benign to low-grade malignancy. Composite hemangioendothelioma (CH) is one of the less commonly encountered variants exhibiting a mixture of elements of other hemangioendothelioma subtypes, such as epithelioid, retiform, and spindle cell. Some authors have identified areas histopathologically equivalent to angiosarcoma within CH, raising the question of the true nature of this neoplasm. Although CH recurs locally, there are only 3 reported cases which metastasized. To date, 26 cases (including the present case) have been described in the literature. Herein, we describe a unique case of CH arising in the background of previous radiation therapy and long-standing lymphedema (classically associated with the development of angiosarcoma-Stewart-Treves syndrome) that harbored higher grade areas but behaved as a low-grade malignant neoplasm. This, in conjunction with the many reported cases of CH-harboring angiosarcoma-like areas, and the occasional association with a history of lymphedema, raises the question of whether this variant of hemangioendothelioma may actually be an angiosarcoma that behaves prognostically better than the conventional type. After careful study of the natural disease progression of the current case and review of the literature, we discuss justification for the continued classification of CH as a low-grade malignancy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23694827</PMID><DateCreated><Year>2013</Year><Month>05</Month><Day>22</Day></DateCreated><DateCompleted><Year>2013</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-0311</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American Journal of dermatopathology</Title><ISOAbbreviation>Am J Dermatopathol</ISOAbbreviation></Journal><ArticleTitle>Composite hemangioendothelioma and its classification as a low-grade malignancy.</ArticleTitle><Pagination><MedlinePgn>517-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DAD.0b013e31827a0d37</ELocationID><Abstract><AbstractText>Hemangioendotheliomas are vascular neoplasms occupying a spectrum of biological potential ranging from benign to low-grade malignancy. Composite hemangioendothelioma (CH) is one of the less commonly encountered variants exhibiting a mixture of elements of other hemangioendothelioma subtypes, such as epithelioid, retiform, and spindle cell. Some authors have identified areas histopathologically equivalent to angiosarcoma within CH, raising the question of the true nature of this neoplasm. Although CH recurs locally, there are only 3 reported cases which metastasized. To date, 26 cases (including the present case) have been described in the literature. Herein, we describe a unique case of CH arising in the background of previous radiation therapy and long-standing lymphedema (classically associated with the development of angiosarcoma-Stewart-Treves syndrome) that harbored higher grade areas but behaved as a low-grade malignant neoplasm. This, in conjunction with the many reported cases of CH-harboring angiosarcoma-like areas, and the occasional association with a history of lymphedema, raises the question of whether this variant of hemangioendothelioma may actually be an angiosarcoma that behaves prognostically better than the conventional type. After careful study of the natural disease progression of the current case and review of the literature, we discuss justification for the continued classification of CH as a low-grade malignancy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNab</LastName><ForeName>Patricia Moody</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, University of South Florida College of Medicine, Tampa, FL 33612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>Brian Christopher</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>L Frank</ForeName><Initials>LF</Initials></Author><Author ValidYN="Y"><LastName>Jukic</LastName><ForeName>Drazen M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Dermatopathol</MedlineTA><NlmUniqueID>7911005</NlmUniqueID><ISSNLinking>0193-1091</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006390" MajorTopicYN="N">Hemangioendothelioma</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018193" MajorTopicYN="N">Neoplasms, Complex and Mixed</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23694827</ArticleId><ArticleId IdType="doi">10.1097/DAD.0b013e31827a0d37</ArticleId><ArticleId IdType="pii">00000372-201306000-00024</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li></region></list><tree><noCountry><name sortKey="Glass, L Frank" sort="Glass, L Frank" uniqKey="Glass L" first="L Frank" last="Glass">L Frank Glass</name><name sortKey="Jukic, Drazen M" sort="Jukic, Drazen M" uniqKey="Jukic D" first="Drazen M" last="Jukic">Drazen M. Jukic</name><name sortKey="Quigley, Brian Christopher" sort="Quigley, Brian Christopher" uniqKey="Quigley B" first="Brian Christopher" last="Quigley">Brian Christopher Quigley</name></noCountry><country name="États-Unis"><region name="Floride"><name sortKey="Mcnab, Patricia Moody" sort="Mcnab, Patricia Moody" uniqKey="Mcnab P" first="Patricia Moody" last="Mcnab">Patricia Moody Mcnab</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001B99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23694827
|texte= Composite hemangioendothelioma and its classification as a low-grade malignancy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23694827" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |